Market Overview:
The global oncology small molecule drugs market is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, rising demand for targeted therapies, and growing investments in oncology research and development (R&D). Based on type, the global oncology small molecule drugs market can be segmented into chemotherapy drugs, immunomodulating drugs, targeted therapy drugs, hormonal therapy, and other types. The chemotherapy drug segment is expected to account for the largest share of the global oncology small molecule drugs market in 2018. This segment is projected to grow at a CAGR of 7.9% during the forecast period from 2018 to 2030. The growth in this segment can be attributed to factors such as increasing incidence of cancer and rising demand for chemotherapeutic agents due to their high efficacy rates against various types of cancers. Based on application, the global oncology small molecule drugs market can be divided into blood cancer, breast cancer Gastrointestinal Cancer (GI), prostate cancer Lung Cancer Other cancers). In terms of revenue share contribution,, blood cancer accounted for majority share followed by GI cancers segments respectively . However ,based upon CAGR Breast Cancer Segment will have highest growth rate over next 10 years .
Product Definition:
Oncology small molecule drugs are a type of cancer treatment that uses small molecules to kill or stop the growth of cancer cells. They are important because they can be more specific than other types of cancer treatments, meaning they can cause fewer side effects.
Chemotherapy Drugs:
Small molecule drugs are the most prominent and extensively used class of medication worldwide. They constitute for more than 90% of all drug prescriptions. Small molecules can easily pass through the blood-brain barrier and have a greater chance to interact with target cells, which makes them an important class of drug for treating neurological disorders such as depression, anxiety, Alzheimer's disease, etc.
The global small molecule oncology drugs market was valued at over USD 30 billion in 2015.
Immunomodulating Drugs:
Immunomodulating drugs are the small molecule that modulate immune system by targeting cytokines, chemokines, and growth factors. These drugs have immunomodulating activity which is evident by their ability to affect T-cell proliferation & differentiation as well as B-cell antibody production.
Application Insights:
The blood cancer segment dominated the market for global oncology small molecule drugs and accounted for 24.9% of the revenue share in 2017 owing to an increase in cases of blood cancers, such as leukemia and myeloma, coupled with a rise in research initiatives by major players.
Rising prevalence of cancer is one of the leading causes of death worldwide. According to WHO, an estimated 1,762,180 people died due to cancer globally (excluding China) in 2016; this number is expected to reach about 2,227,720 by 2030 if current trends continue. Therefore., finding new therapeutic solutions would help reduce mortality rates associated with this disease which would result into increased demand for SMD drugs during forecast period.
Regional Analysis:
North America dominated the global oncology small molecule drugs market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; coupled with favorable government initiatives pertaining to drug development. For instance, in November 2016, the FDA approved two new drugs from Pfizer for treatment of Metastatic Castration-Resistant Prostate Cancer (CRPC). These approvals were based on a study conducted by National Cancer Institute that concluded that these medicines may help reduce prostate cancer risk factors associated with increased risk of lethal CRPC progression.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising patient awareness levels regarding available treatment options and availability of effective therapies for various types of cancers. In addition, increasing number and scope of clinical trials being undertaken by companies present in this region are also anticipated to drive regional growth during the forecast period.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for oncology small molecule drugs market. According to World Health Organization (WHO), the number of new cases diagnosed with cancer every year is expected to rise from 14 million in 2012 to 22 million by 2030. This will create a huge demand for oncology small molecule drugs, which will drive the market growth during the forecast period.
- Rising prevalence of lifestyle diseases: The rising prevalence of lifestyle diseases such as obesity and diabetes is also contributing to the growth of oncology small molecule drugs market. These diseases are known risk factors for various types of cancers, which is creating a high demand for effective treatment options, thereby driving the market growth.
- Technological advancements in drug discovery and development: The technological advancements in drug discovery and development are leading to introduction of novel therapeutics that are more efficacious and have fewer side effects as compared to traditional therapies, thus propelling the growth prospects for oncology small molecule drugs market over next few years . For instance, Incyte Corporation’s Jakafi (ruxolitinib) was approved by US FDA in November 2011 as first-line therapy for patients with myelofibrosis who do not respond or intolerant to other therapies including hydroxyurea . This approval has further boosted adoption rate Jakafi globally due its better safety profile than other available treatments optionsfor myelofibrosis patients . Thus
Scope Of The Report
Report Attributes
Report Details
Report Title
Oncology Small Molecule Drugs Market Research Report
By Type
Chemotherapy Drugs, Immunomodulating Drugs, Targeted Therapy Drugs, Hormonal Therapy, Other
By Application
Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Other
By Companies
Roche, Novartis, Pfizer, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, AbbVie, Sanofi, Takeda, Eli Lilly, Bayer, AstraZeneca, Astellas, Merck, Biogen Idec, Eisai, Teva, Otsuka, Ipsen, Gilead Sciences, Exelixis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
219
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Oncology Small Molecule Drugs Market Report Segments:
The global Oncology Small Molecule Drugs market is segmented on the basis of:
Types
Chemotherapy Drugs, Immunomodulating Drugs, Targeted Therapy Drugs, Hormonal Therapy, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Novartis
- Pfizer
- Celgene
- Bristol-Myers Squibb
- Amgen
- Johnson & Johnson
- AbbVie
- Sanofi
- Takeda
- Eli Lilly
- Bayer
- AstraZeneca
- Astellas
- Merck
- Biogen Idec
- Eisai
- Teva
- Otsuka
- Ipsen
- Gilead Sciences
- Exelixis
Highlights of The Oncology Small Molecule Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy Drugs
- Immunomodulating Drugs
- Targeted Therapy Drugs
- Hormonal Therapy
- Other
- By Application:
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Lung Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oncology Small Molecule Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oncology small molecule drugs are medications used to treat cancer. These drugs can be grouped into two main types: tyrosine kinase inhibitors (TKIs) and receptor tyrosine kinases (RTKs). TKIs work by blocking the activity of specific proteins that are involved in the growth and spread of cancer cells. RTKs work by targeting specific genes that play a role in tumor growth or survival.
Some of the major players in the oncology small molecule drugs market are Roche, Novartis, Pfizer, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, AbbVie, Sanofi, Takeda, Eli Lilly, Bayer, AstraZeneca, Astellas, Merck, Biogen Idec, Eisai, Teva, Otsuka, Ipsen, Gilead Sciences, Exelixis.
The oncology small molecule drugs market is expected to grow at a compound annual growth rate of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oncology Small Molecule Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oncology Small Molecule Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oncology Small Molecule Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oncology Small Molecule Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oncology Small Molecule Drugs Market Size & Forecast, 2018-2028
4.5.1 Oncology Small Molecule Drugs Market Size and Y-o-Y Growth
4.5.2 Oncology Small Molecule Drugs Market Absolute $ Opportunity
Chapter 5 Global Oncology Small Molecule Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Oncology Small Molecule Drugs Market Size Forecast by Type
5.2.1 Chemotherapy Drugs
5.2.2 Immunomodulating Drugs
5.2.3 Targeted Therapy Drugs
5.2.4 Hormonal Therapy
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Oncology Small Molecule Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Oncology Small Molecule Drugs Market Size Forecast by Applications
6.2.1 Blood Cancer
6.2.2 Breast Cancer
6.2.3 Gastrointestinal Cancer
6.2.4 Prostate Cancer
6.2.5 Lung Cancer
6.2.6 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oncology Small Molecule Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oncology Small Molecule Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Oncology Small Molecule Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Oncology Small Molecule Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Oncology Small Molecule Drugs Market Size Forecast by Type
9.6.1 Chemotherapy Drugs
9.6.2 Immunomodulating Drugs
9.6.3 Targeted Therapy Drugs
9.6.4 Hormonal Therapy
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Oncology Small Molecule Drugs Market Size Forecast by Applications
9.10.1 Blood Cancer
9.10.2 Breast Cancer
9.10.3 Gastrointestinal Cancer
9.10.4 Prostate Cancer
9.10.5 Lung Cancer
9.10.6 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Oncology Small Molecule Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Oncology Small Molecule Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Oncology Small Molecule Drugs Market Size Forecast by Type
10.6.1 Chemotherapy Drugs
10.6.2 Immunomodulating Drugs
10.6.3 Targeted Therapy Drugs
10.6.4 Hormonal Therapy
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Oncology Small Molecule Drugs Market Size Forecast by Applications
10.10.1 Blood Cancer
10.10.2 Breast Cancer
10.10.3 Gastrointestinal Cancer
10.10.4 Prostate Cancer
10.10.5 Lung Cancer
10.10.6 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Oncology Small Molecule Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Oncology Small Molecule Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Oncology Small Molecule Drugs Market Size Forecast by Type
11.6.1 Chemotherapy Drugs
11.6.2 Immunomodulating Drugs
11.6.3 Targeted Therapy Drugs
11.6.4 Hormonal Therapy
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Oncology Small Molecule Drugs Market Size Forecast by Applications
11.10.1 Blood Cancer
11.10.2 Breast Cancer
11.10.3 Gastrointestinal Cancer
11.10.4 Prostate Cancer
11.10.5 Lung Cancer
11.10.6 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Oncology Small Molecule Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Oncology Small Molecule Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Oncology Small Molecule Drugs Market Size Forecast by Type
12.6.1 Chemotherapy Drugs
12.6.2 Immunomodulating Drugs
12.6.3 Targeted Therapy Drugs
12.6.4 Hormonal Therapy
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Oncology Small Molecule Drugs Market Size Forecast by Applications
12.10.1 Blood Cancer
12.10.2 Breast Cancer
12.10.3 Gastrointestinal Cancer
12.10.4 Prostate Cancer
12.10.5 Lung Cancer
12.10.6 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Oncology Small Molecule Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Oncology Small Molecule Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Oncology Small Molecule Drugs Market Size Forecast by Type
13.6.1 Chemotherapy Drugs
13.6.2 Immunomodulating Drugs
13.6.3 Targeted Therapy Drugs
13.6.4 Hormonal Therapy
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Oncology Small Molecule Drugs Market Size Forecast by Applications
13.10.1 Blood Cancer
13.10.2 Breast Cancer
13.10.3 Gastrointestinal Cancer
13.10.4 Prostate Cancer
13.10.5 Lung Cancer
13.10.6 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oncology Small Molecule Drugs Market: Competitive Dashboard
14.2 Global Oncology Small Molecule Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Novartis
14.3.3 Pfizer
14.3.4 Celgene
14.3.5 Bristol-Myers Squibb
14.3.6 Amgen
14.3.7 Johnson & Johnson
14.3.8 AbbVie
14.3.9 Sanofi
14.3.10 Takeda
14.3.11 Eli Lilly
14.3.12 Bayer
14.3.13 AstraZeneca
14.3.14 Astellas
14.3.15 Merck
14.3.16 Biogen Idec
14.3.17 Eisai
14.3.18 Teva
14.3.19 Otsuka
14.3.20 Ipsen
14.3.21 Gilead Sciences
14.3.22 Exelixis
